
Multicentre Study Highlights Exceptional Surgical Efficiency of the Molteno3® Glaucoma Drainage Device

Adelaide, Australia, 5 August 2020 – Nova Eye Medical Limited (ASX: EYE)(Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to report the results of multicentre clinical study which reinforces the surgical utility of the Molteno3® glaucoma drainage device, as compared to the competing Baerveldt® device (Johnson & Johnson).

Published in *Ophthalmology*, the study reported the surgical time of the Molteno3® to be 15.7 minutes faster than the Baerveldt®. This constitutes a significant time saving for physicians and permits the optimal utilisation of operation room resources.

Clinical outcomes for the Molteno3® were also favourable. Reduction in intraocular pressure (IOP) for the Molteno3® at the 24-month follow-up at 16.6 mmHg, compared to the Baerveldt® at 17.0 mmHg. In addition, the overall rates of failure were 27.5% for the Molteno3® compared to 45.5% for the Baerveldt®.

According to Victor Previn, Chairman of Nova Eye Medical, the study results validate an extensive body of clinical work that supports the clinical efficacy of the Molteno3®.

“The Molteno3® is approximately 40% smaller than the Baerveldt®. Historically, there has been a perception that a larger glaucoma drainage device is needed in order to achieve long-term IOP reduction. The Molteno3® has been designed with a unique patented geometry, and at a smaller size, to achieve the same efficacy outcomes as larger devices with the benefits of a simplified and shorter surgical procedure.”

“Offering enhanced surgical utility and optimised clinical outcomes, the Molteno3® is a win-win for physicians. With the compelling results of this study, we will leverage our existing glaucoma-focused sales, marketing and clinical infrastructure to grow the Molteno3® physician base in the USA and globally,” added Mr. Previn.

To access the publication, please follow the link below:

[https://www.opthalmologyglaucoma.org/article/S2589-4196\(19\)30304-7/abstract%22](https://www.opthalmologyglaucoma.org/article/S2589-4196(19)30304-7/abstract%22)

This release dated 5 August 2020 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

For further information please contact:

Company

Victor Previn
Executive Chairman
Nova Eye Medical Limited
vprevin@nova-eye.com

Investors

Dr. Tom Duthy
Investor Relations & Corporate Development
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com

Media

Kate Hunt
Head of Marketing
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com